JennyKimMD

Hematologic Oncology

Senior Director, Clinical Research. Kite, A Gilead Company

Dr. Kim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2004 - 2007
Keck School of Medicine of the University of Southern CaliforniaClass of 2004

PubMed

1 citations
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett, Lazaros J Lekakis, Caron A Jacobson
Transplantation and Cellular Therapy. 2024-11-01
2 citations
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose
Bone Marrow Transplantation. 2024-03-01
2 citations
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.
Michael D Jain, David B Miklos, Caron A Jacobson, John M Timmerman, Jennifer Sun
Clinical Cancer Research. 2023-10-13

Abstracts/Posters

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
Jenny J. Kim, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Jenny J. Kim, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma
Jenny J. Kim, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019